Skip to main content

Table 4 Overall survival; multivariable analysis including Z-4OHtam, Z-endoxifen, and AAS

From: Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

Continuous variables

Categorical variables

Factor

HR per unit*

95% CI

P

Factor

 

HR

95% CI

P

Z-4OHtam

   

Z-4OHtam

> 3.26 nM

1

  

Adjusted

0.81

0.66–0.99

0.040

 

≤ 3.26 nM

4.86

1.88–12.54

0.001

Unadjusted

0.85

0.70–1.02

0.077

pT

1

1

  
     

2

2.59

1.11–6.05

0.028

    

pN

Negative

1

  
     

Positive

2.89

1.12–7.49

0.029

    

Chemotherapy

Yes

1

  
     

No

2.34

0.90– 6.11

0.083

Z-endoxifen

   

Z–endoxifen

> 9.00 nM

1

  

Adjusted

0.99

0.96–1.02

0.365

 

≤ 9.00 nM

5.65

2.00–16.00

0.001

Unadjusted

0.99

0.97–1.02

0.580

pT

1

1

  
     

2

2.44

1.08–5.49

0.032

    

pN

Negative

1

  
     

Positive

2.40

0.99–5.80

0.052

    

Chemotherapy

Yes

1

  
     

No

3.41

1.24–9.39

0.017

AAS

   

AAS

> 16.7

1

  

Adjusted

0.99

0.97–1.01

0.313

 

≤ 16.7

8.39

2.90–24.26

<0.001

Unadjusted

0.99

0.98–1.10

0.532

pT

1

1

  
     

2

2.60

1.15–5.91

0.022

    

pN

Negative

1

  
     

Positive

3.40

1.26–9.15

0.016

    

Chemotherapy

Yes

1

  
     

No

2.67

1.03–6.94

0.044

  1. * Change in hazard ratio (HR) per 1 nM increase in serum concentration of Z-4OHtam, Z-endoxifen, change in HR per 1 unit Antiestrogenic Activity Score (AAS; dimensionless)
  2. Adjusting variables: pT, pN, histological grade, estrogen receptor, progesterone receptor, age, and chemotherapy
  3. CI confidence interval, pN pathologic node status, pT pathologic tumor size